PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas (vol 113, pg 1020, 2015)

被引：9
|
作者：
Black, Jonathan D.
Lopez, Salvatore
Cocco, Emiliano
Bellone, Stefania
Altwerger, Gary
Schwab, Carlton L.
English, Diana P.
Bonazzoli, Elena
Predolini, Federica
Ferrari, Francesca
Ratner, Elena
Silasi, Dan-Arin
Azodi, Masoud
Schwartz, Peter E.
Santin, Alessandro D.
机构：
来源：
BRITISH JOURNAL OF CANCER | 2015年 / 113卷 / 11期
关键词：
D O I：
10.1038/bjc.2015.388
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Correction to: British Journal of Cancer (2015) 113, 1020–1026. doi:10.1038/bjc.2015.306 It has been brought to our attention that there is an error in Figure 3 of the above paper published in advance online on 1 September 2015. The original label above the figure reads as ‘ARK-2 E93Q’. It should becorrected to ‘ARK-2 R93Q’.
引用
收藏
页码：1641 / 1641
页数：1
相关论文
共 27 条
  • [1] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Black, J. D.
    Lopez, S.
    Cocco, E.
    Bellone, S.
    Altwerger, G.
    Schwab, C. L.
    English, D. P.
    Bonazzoli, E.
    Predolini, F.
    Ferrari, F.
    Ratner, E.
    Silasi, D. A.
    Azodi, M.
    Schwartz, P. E.
    Santin, A. D.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 596 - 596
  • [2] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Black, Jonathan D.
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Altwerger, Gary
    Schwab, Carlton L.
    English, Diana P.
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2015, 113 (07) : 1020 - 1026
  • [3] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Jonathan D Black
    Salvatore Lopez
    Emiliano Cocco
    Stefania Bellone
    Gary Altwerger
    Carlton L Schwab
    Diana P English
    Elena Bonazzoli
    Federica Predolini
    Francesca Ferrari
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E Schwartz
    Alessandro D Santin
    British Journal of Cancer, 2015, 113 : 1020 - 1026
  • [4] Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Jonathan D Black
    Salvatore Lopez
    Emiliano Cocco
    Stefania Bellone
    Gary Altwerger
    Carlton L Schwab
    Diana P English
    Elena Bonazzoli
    Federica Predolini
    Francesca Ferrari
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E Schwartz
    Alessandro D Santin
    British Journal of Cancer, 2015, 113 : 1641 - 1641
  • [5] Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
    Pelligra, Silvia
    Buza, Natalia
    Hui, Pei
    Bellone, Stefania
    Zeybek, Burak
    Ratner, Elena
    Schwartz, Peter E.
    Scambia, Giovanni
    Santin, Alessro D.
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 32
  • [6] Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
    Lopez, Salvatore
    Schwab, Carlton L.
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    English, Diana P.
    Schwartz, Peter E.
    Rutherford, Thomas
    Angioli, Roberto
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 312 - 317
  • [7] Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma (vol 32, 100554, 2020)
    Pelligra, S.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 35
  • [8] Alterations in PTEN/PIK3CA/AKT pathway does not modify trastuzumab response in HER-2/NEU breast carcinomas
    Lerma, E.
    Gallardo, A.
    Peiro, G.
    Planelles, M.
    Vergara, C.
    Solis, J.
    Dominguez, N.
    Alonso, C.
    Barnadas, A.
    Prat, J.
    HISTOPATHOLOGY, 2008, 53 : 47 - 48
  • [9] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
    Rexer, B. N.
    Chakrabarty, A.
    Rinehart, C.
    Chang, J.
    Engelman, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 266S - 267S
  • [10] PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
    Bonazzoli, Elena
    Cocco, Emiliano
    Lopez, Salvatore
    Bellone, Stefania
    Zammataro, Luca
    Bianchi, Anna
    Manzano, Aranzazu
    Yadav, Ghanshyam
    Manara, Paola
    Perrone, Emanuele
    Haines, Kaitlin
    Espinal, Mariana
    Dugan, Katherine
    Menderes, Gulden
    Altwerger, Gary
    Han, Chanhee
    Zeybek, Burak
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (01) : 158 - 164
123